06th week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120034156 | Artificial cells - The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products. | 2012-02-09 |
20120034157 | Artificial cells - The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products. | 2012-02-09 |
20120034158 | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis corresponding compositions and kits - An immuno-imaging agent for the detection of tumor cells by means of an immuno-imaging technique, including at least one of:
| 2012-02-09 |
20120034159 | ANTIBODIES THAT BIND BOTH BCMA AND TACI - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor, and the B-cell maturation (BCMA) receptor. | 2012-02-09 |
20120034160 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2012-02-09 |
20120034161 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN - Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other a cyclooctene or cyclooctyne. | 2012-02-09 |
20120034162 | Fullerene Assisted Cell Penetrating Peptides - A composition and method is described for intracellular delivery of fullerene containing peptides. The composition and method involve fullerene-substituted phenylalanine as part of a peptide based delivery system. The presence of a fullerene-substituted amino acid in a peptide is found to alter the intracellular transport properties of the peptide. | 2012-02-09 |
20120034163 | NON-INVASIVE TOOLS FOR DETECTING VULNERABLE ATHEROSCLEROTIC PLAQUES - The present invention relates to a polypeptide comprising the sequence RILAR (SEQ ID NO: 3), the use thereof in imaging methods, in diagnostic or prognostic methods and for use as a medicament. | 2012-02-09 |
20120034164 | TRUNCATED CAR PEPTIDES AND METHODS AND COMPOSITIONS USING TRUNCATED CAR PEPTIDES - Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated CAR peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest. | 2012-02-09 |
20120034165 | IMAGING THE CENTRAL NERVOUS SYSTEM WITH PURINERGIC P2X7 RECEPTOR BINDING AGENTS - The present invention provides novel compounds which may be used as in vivo imaging agents. The compounds of the invention are useful in a method to image the expression of P2X7 receptors in a subject, as a means to facilitate the diagnosis of a range of disease states. | 2012-02-09 |
20120034166 | AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF - The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-β(1-42) proteins, the production and use thereof. | 2012-02-09 |
20120034167 | TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER - The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer. | 2012-02-09 |
20120034168 | Isolated Monoclonal Antibody or Fragment Thereof Binding Prostate Specific Membrane Antigen, Conjugates and Uses Thereof - An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases. | 2012-02-09 |
20120034169 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 2012-02-09 |
20120034170 | Nanobubbles Useful As An Ultrasonic Contrast Agent For The Lymphatic System - A composition is provided accompanying nanoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes. | 2012-02-09 |
20120034171 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 2012-02-09 |
20120034172 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases. | 2012-02-09 |
20120034173 | Aerosol Hairspray Product for Styling and/or Shaping Hair - An aerosol hairspray product for styling and/or shaping hair. The product comprises a container for storing a hairstyling formulation and a propellant, wherein the container wall comprises at least about 80% plastic material by total weight of the container. The product also comprises a hairstyling formulation comprising from about 50% to about 99% water by total weight of the hairstyling formulation and propellant. Furthermore, the product comprises less than 15% volatile organic compound by total weight of the hairstyling formulation and propellant. | 2012-02-09 |
20120034174 | COMPOSITION - The present invention provides a surfactant product in the form of a solid comprising a surfactant, sodium carbonate and cream of tartar. | 2012-02-09 |
20120034175 | Compositions And Methods For Reducing Appearance Of Under-Eye Dark Circles - A cosmetic or dermatological composition is provided for reducing appearance of under-eye dark circles, which contains at least one bicyclic monoterpene diol and at least one skin lightening agent in a cosmetically or pharmaceutically acceptable carrier. The composition may further contain at least one anti-angiogenic agent and/or at least one anti-inflammatory agent. | 2012-02-09 |
20120034176 | SULPHURATED DERIVATIVES OF RESORCINOL, PREPARATION OF SAME AND COSMETIC USES THEREOF - The present invention relates to a compound of the general formula (I) where: X═S, SO or SO | 2012-02-09 |
20120034177 | METHOD OF WHITENING SKIN - Disclosed are: a skin whitening agent comprising, as an active ingredient, a complex of carbonic acid and/or bicarbonic acid, a metal and an LF, a decomposition product of the complex, or a complex of carbonic acid and/or bicarbonic acid, a metal and a decomposition product of an LF; and a food, beverage, feed or cosmetic comprising the skin whitening agent. The skin whitening agent can be ingested safely on a daily basis, and exhibits an excellent skin whitening effect. | 2012-02-09 |
20120034178 | PIGMENT MIXTURES - The present invention relates to novel pigment mixtures comprising at least two different particulate components A and B. The first component A comprises titanium suboxide(s), a titanium oxynitride or a titanium nitride species. Component B particle comprises inorganic, or organic pigments. The titanium suboxide particles display a bluish metallic luster, are new and form a further aspect of the present invention. When combined with particles from component B such as variously coated micas, for example, the bluish or bluish/black metallic color effect from component A leads to special color effects in the various mixtures. | 2012-02-09 |
20120034179 | STABLE SOLID DEODORANT PRODUCT AND METHOD FOR MANUFACTURING SAME - The present invention provides a deodorant formulation having improved efficacy and stability. The deodorant formulation comprises propanediol, ethylhexylglycerin, and grapefruit seed extract as the principal deodorizing actives. The combination of these deodorizing active ingredients results in a formulation with strong efficacy. The deodorant formulation of the invention may further be formed into a stable solid stick product in accordance with the methods outlined herein. | 2012-02-09 |
20120034180 | HAIR STYLING COMPOSITION - A hair care composition comprising from 0.001 wt % to 20 wt % of the total composition of a titanium salt. | 2012-02-09 |
20120034181 | AQUEOUS CLEANSING COMPOSITION - The present invention is related to an aqueous cleansing composition for keratin fibres especially human hair with excellent conditioning effects. Accordingly, first object of the present invention is an aqueous cleansing composition for keratin fibres, especially human hair, comprising at least one foaming surfactant selected from anionic, non-ionic and amphoteric ones and at least one dipeptide. The most preferred is carnosine and is of R-alanin and L-histidine. | 2012-02-09 |
20120034182 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to a conditioning composition for hair comprising at least one hair conditioning agent and at least one dipeptide. At least one hair conditioning agent is a compound according to general structure | 2012-02-09 |
20120034183 | COMPOSITIONS AND METHODS FOR GROWING EMBRYONIC STEM CELLS - Compositions including topical formulations comprising secreted products obtained from the culture medium of human embryonic germ (EG) cell derivatives and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions. | 2012-02-09 |
20120034184 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION - The present invention relates to the use of nucleoside derivatives of formula I | 2012-02-09 |
20120034185 | ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEROF AND METHODS OF USE - The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis. | 2012-02-09 |
20120034186 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER - Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throughput screen identified compounds that inhibit the PTP Shp2. Several compounds were identified that selectively inhibit Shp2 over Shp1 with low to sub-micromolar activity. Also disclosed are methods of inhibiting a protein tyrosine phosphatase in a cell and treating cancer through selective inhibition of Shp2. | 2012-02-09 |
20120034187 | Hepatitis C Inhibitor Compounds - Compounds of formula (I): | 2012-02-09 |
20120034188 | Akt Nucleic Acids, Polypeptides, and Uses Thereof - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis. | 2012-02-09 |
20120034189 | MEANS AND METHODS FOR DURABLE INHIBITION OF PATHOGENS - The invention provides improved nucleic acids for anti-HIV therapy. The invention further provides selection methods which are capable of predicting already at an early stage of development whether promising anti-pathogenic candidate compounds will be suitable for therapeutic use in vivo. | 2012-02-09 |
20120034190 | YEAST STRAINS AND THEIR USES IN THE PRODUCTION OF LIPIDS - The invention is directed to isolated microorganisms, as well as biomasses, cultures, microbial oils, and compositions thereof. The invention also provides methods of producing the microbial oils and methods of using the isolated microorganisms, biomasses, and microbial oils. | 2012-02-09 |
20120034191 | EXTRACELLULAR MATRIX COMPOSITIONS FOR TISSUE REGENERATION - The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals. | 2012-02-09 |
20120034192 | COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING - The invention provides compositions and methods of use to enhance reprogramming of mammalian cells. Certain compositions and methods of the invention are of use to enhance generation of induced pluripotent stem cells by reprogramming somatic cells. Certain compositions and methods of the invention are of use to enhance reprogramming of pluripotent mammalian cells to a differentiated cell type. Certain compositions and methods of the invention are of use to enhance reprogramming of differentiated mammalian cells of a first cell type to differentiated mammalian cells of a second differentiated cell type. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that enhances or contributes to reprogramming mammalian cells. Certain of the inventive compositions and methods relate to inhibiting histone methylation. | 2012-02-09 |
20120034193 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS - An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health. | 2012-02-09 |
20120034194 | Somatic Stem Cells - A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses. | 2012-02-09 |
20120034195 | PLACENTAL STEM CELLS DERIVE FROM POST-PARTUM MANMALIAN PLACENTA, AND USES AND METHODS OF TREATMENT USING SAID CELLS - The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. | 2012-02-09 |
20120034196 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK) - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 2012-02-09 |
20120034197 | HIV-RESISTANT STEM CELLS AND USES THEREOF - Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS. | 2012-02-09 |
20120034198 | CARRIERS FOR STORAGE AND DELIVERY OF BIOLOGICS - Processes and formulations for the administration and storage of dried microorganisms are disclosed. Microbial based products containing prebiotic formulations for administration and for storage of microorganisms are disclosed. These prebiotic formulations can act both for administration into an animal or human subject and act as to preserve or store the dried microorganisms. | 2012-02-09 |
20120034199 | MONOGASTRIC ANIMAL FEED - The present invention relates an improved feed additive or food supplement formulation obtained from more than one strain of Lactic acid bacteria. The feed additive or supplements is used to feed monogastric animals such as avian, fowl. Moreover, the feed provides better growth and feed utilization for monogastric animals. Further, the animal feed can be used for controlling food intake in the animals. | 2012-02-09 |
20120034200 | Formulations Including Digestive Enzymes, Polysorbate-Based Surfactants and Probiotics - Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of | 2012-02-09 |
20120034201 | COMPOSITION FOR REGULATING LIPID METABOLISM - This invention concerns a nutraceutical and/or food composition for regulating, among other things, lipid metabolism in humans and animals, and methods of use of said nutraceutical and/or food composition. | 2012-02-09 |
20120034202 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): | 2012-02-09 |
20120034203 | Methods for Killing or Inhibiting Growth of Mycobacteria - The present invention provides a method for killing or inhibiting growth of Mycobacteria, by contacting the Mycobacteria with a haloperoxidase, hydrogen peroxide, chloride ions and/or bromide ions, and ammonium ions. | 2012-02-09 |
20120034204 | FERTILIZATION MODULATION COMPOUNDS AND PROCESS FOR IMPLEMENTING THEM - This invention relates to fertilization modulation compounds and process for implementing them. | 2012-02-09 |
20120034205 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE - The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | 2012-02-09 |
20120034206 | BREAST CANCER ERADICATION PROGRAM - A method of treating breast cancer that is at least partially ER | 2012-02-09 |
20120034207 | PRODUCTION OF HER RECEPTOR ANTIBODIES IN PLANT - A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants. | 2012-02-09 |
20120034208 | Treating Breast Cancer with Anti-IL-19 Antibody - Use of an anti-IL-19 antibody for treating breast cancer, either alone or in combination with an anti-IL-20 and/or anti-IL-20R1 antibody. | 2012-02-09 |
20120034209 | Treatment - The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease. | 2012-02-09 |
20120034210 | COMPOSITIONS FOR POTENTIATING APOPOSIS SIGNALS IN TUMOUR CELLS - The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5. | 2012-02-09 |
20120034211 | EGFR antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2012-02-09 |
20120034212 | Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases - The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors. | 2012-02-09 |
20120034213 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES - The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient. | 2012-02-09 |
20120034214 | METHODS AND KITS FOR DETERMINING THE PROGNOSIS OF PULMONARY SARCOIDOSIS - The invention provides a method for determining the prognosis of pulmonary sarcoidosis in an individual subject, comprising conducting gene expression analysis on a sample from the subject. The sample is obtained by bronchoscopy under procedural methods not requiring general anaesthesia. | 2012-02-09 |
20120034215 | ANTI-MST1R ANTIBODIES AND USES THEREOF - The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2012-02-09 |
20120034216 | SPIROKETALS - The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests. | 2012-02-09 |
20120034217 | ANTI-NEOPLASTIC COMPOSITIONS COMPRISING EXTRACTS OF BLACK COHOSH - The present invention provides a composition for use in treating or preventing neoplasia, comprising an effective actein. The present invention also provides a composition for use in treating or preventing neoplasia, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh. The present invention further provides a combination of anti-neoplastic agents, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh and an effective anti-neoplastic amount of at least one additional chemopreventive or chemotherapeutic agent. Methods for treating and preventing neoplasia are also provided. | 2012-02-09 |
20120034218 | RBM3 in Colorectal Cancer Prognostics - The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and | 2012-02-09 |
20120034219 | USES OF IL-23 AGONISTS AND ANTAGONISTS; RELATED REAGENTS - Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor. | 2012-02-09 |
20120034220 | Mucin Fusion Polypeptide Vaccines, Compositions And Methods Of Use Thereof - The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins. | 2012-02-09 |
20120034221 | T-Cell Receptor Antibodies And Methods of Use Thereof - The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the α chain of the TCR, or otherwise specifically binds the α chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies. | 2012-02-09 |
20120034222 | Nitric Oxide Generating Medical Devices - Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided. | 2012-02-09 |
20120034223 | METHODS OF IMPROVING THE THERAPEUTIC EFFICACY AND UTILITY OF ANTIBODY FRAGMENTS - The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies. | 2012-02-09 |
20120034224 | Treating Rheumatoid Arthritis with Anti-IL-19 Antibody - Treating rheumatoid arthritis with an anti-IL-19 antibody, optionally in combination with another anti-RA agent. | 2012-02-09 |
20120034225 | Suppressing Bone Loss with Anti-IL-19 Antibody - A method of suppressing bone loss with an anti-IL-19 antibody, optionally in combination with an anti-IL-20 antibody or an anti-RANKL antibody. | 2012-02-09 |
20120034226 | DIAGNOSTIC METHOD OF SKIN INFLAMMATORY DISEASE - The invention provides a method of determining (or diagnosing) the presence or absence of a functional abnormality in the skin barrier, a kit therefor, a method of ameliorating a functional abnormality in the skin barrier based on the onset mechanism, and a drug therefor. The method of determining the presence or absence of a functional abnormality in the skin barrier comprises measuring the expression of a protease and/or an inhibitor thereof on the skin surface of a test object, and the like. | 2012-02-09 |
20120034227 | MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER - The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer. | 2012-02-09 |
20120034228 | CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 2012-02-09 |
20120034229 | MONOCLONAL ANTIBODIES DIRECTED AGAINST LG4-5 DOMAIN OF ALPHA3 CHAIN OF HUMAN LAMININ-5 - The present invention relates to a monoclonal antibody binding to the LG4/5 domain of chain alpha3 of human protein laminin-5, wherein said monoclonal antibody inhibits the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, in particular 1H12 monoclonal antibody produced by the hybridoma cell line named 1H12 deposited on Jan. 8, 2008 at the C. N. C. M. under number 1-3890, as well as chimerized, humanized derivatives and fragments thereof, and nucleic acid sequences encoding them, as well as vectors and host cells expressing them. The invention further relates to the medical application of such antibodies, in particular for treating cancer. | 2012-02-09 |
20120034230 | Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA - The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against | 2012-02-09 |
20120034231 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 2012-02-09 |
20120034232 | TLR3 BINDING AGENTS - The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like. | 2012-02-09 |
20120034233 | Methods of Treating an Overweight or Obese Subject - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis. | 2012-02-09 |
20120034234 | METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS - The invention is in the field of molecular immunology, more in particular in the field of the prevention or treatment of autoimmune diseases, more in particular systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention therefore relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced. | 2012-02-09 |
20120034235 | Marker for Liver-Cancer Diagnosis and Recurrence and Survival Prediction, a Kit Comprising the Same, and Prognosis Prediction in Liver-Cancer Patients Using the Marker - A composition for detecting a marker for the diagnosis or prognosis of liver cancer is disclosed. The composition includes an agent capable of assessing the expression level of UQCRH (ubiquinol-cytochrome c reductase hinge protein). In addition, a kit having the composition, a microarray for the diagnosis of liver cancer using the marker, and a method for detecting the marker, and predicting recurrence following surgery in liver cancer patients are disclosed. The marker is able to contribute to the early diagnosis of liver cancer and prediction of recurrence following surgery and survival of liver cancer patients who have undergone hepatic resection, and also is significant for being a promising therapeutic target for liver cancer. | 2012-02-09 |
20120034236 | CO-TARGETING OF AURORA A KINASE AND LIM KINASE 1 FOR CANCER THERAPY - Disclosed herein are therapies for treating or preventing reoccurrence of cancer. The therapies involved inhibition of LIMK1 in conjunction with AurKA inhibition. Specifically exemplified herein is the administration of an AurKA inhibitor in conjunction with a LIMK1 RNA interfering molecule. | 2012-02-09 |
20120034237 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 2012-02-09 |
20120034238 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS VIRUS INFECTION - The present invention relates to a method for treating hepatitis virus infection comprising administering to a subject infected with a hepatitis virus an effective amount of a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using | 2012-02-09 |
20120034239 | PROTEINS WITH IMPROVED SOLUBILITY AND METHODS FOR PRODUCING AND USING SAME - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 2012-02-09 |
20120034240 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 2012-02-09 |
20120034241 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the | 2012-02-09 |
20120034242 | CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS - The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one additional cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or cancer therapeutic agent or treatment as a monotherapy. | 2012-02-09 |
20120034243 | Method of Administering an Antibody - Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month. | 2012-02-09 |
20120034244 | METHODS OF TREATING SECONDARY BONE TUMORS WITH ANTIBODIES AGAINST PDGFR ALPHA - The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents. | 2012-02-09 |
20120034245 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2012-02-09 |
20120034246 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-02-09 |
20120034247 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-02-09 |
20120034248 | NOVEL AGONISTS OF TOLL-LIKE RECEPTOR 3 AND METHODS OF THEIR USE - TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided. | 2012-02-09 |
20120034249 | Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 2012-02-09 |
20120034250 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | 2012-02-09 |
20120034251 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER BY INDUCING DENDRITIC CELL-LIKE DIFFERENTIATION FROM MONOCYTES TO IMPROVE ANTICANCER IMMUNE ACTIVITY - According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. | 2012-02-09 |
20120034252 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE - The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2012-02-09 |
20120034253 | Influenza Vaccines, Antigens, Compositions, and Methods - The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for the production of such antigens in plants. In some embodiments, influenza antigens include hemagglutinin polypeptides, neuraminidase polypeptides, and/or combinations thereof. | 2012-02-09 |
20120034254 | ANTIGENIC CLOAKING AND ITS USE - Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject. | 2012-02-09 |
20120034255 | CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed. | 2012-02-09 |